Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Insulin Glargine in Type 2 Diabetic Patients (TARGET)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: June 30, 2006
Last updated: September 14, 2009
Last verified: September 2009


  • To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c < 7%)


  • To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic, non-symptomatic and nocturnal hypoglycaemia)
  • To investigate whether beta cell function is preserved if this therapy is initiated before 2nd OAD (oral anti-diabetic drug) failure

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: Insulin Glargine
Drug: Glyburide
Drug: Glyclazide
Drug: Glimiperide
Drug: Glipizide
Drug: Metformin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • A1c values [ Time Frame: At baseline and 24 weeks ]

Secondary Outcome Measures:
  • Adverse events including hypoglycemia [ Time Frame: From the beginning to the end of the study ]

Enrollment: 387
Study Start Date: June 2006
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Administration of Insulin Glargine and Sulfonylurea or Metformin
Drug: Insulin Glargine
Throughout study period
Drug: Metformin
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Active Comparator: 2
Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
Drug: Glyburide
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Drug: Glyclazide
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Drug: Glimiperide
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Drug: Glipizide
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Drug: Metformin
Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes patients with first OAD (Sulfonylurea [SU] or Metformin) failure
  • Patients who are insulin naive (unless it was used for gestational diabetes or if insulin therapy was less than 1 week)
  • Serum creatinine ≤ 1.5mg/dL
  • BMI: 21-41 kg/m²
  • 7.5%< A1c <11%
  • Fasting plasma glucose > 7.5mmol/L
  • On diet and exercise therapy and stable OAD treatment (SU or metformin > ½ maximal dose)for more than 1 month prior to enrolment
  • Women not of childbearing potential (sterilization procedure done or menopausal > 2 years), or if of childbearing potential, agree to take reliable contraceptive measures during the study
  • Able and willing to monitor blood glucose
  • Able and willing to perform 7 point blood glucose self monitoring at baseline, 12 week and 24 week
  • Understand that there is a 50% chance of being randomized to the insulin treatment arm and is willing to self inject insulin

Exclusion Criteria:

  • Type 1 diabetes
  • Acute complication of diabetes, such as diabetic ketoacidosis and hyperosmolar coma
  • Pregnancy, breast-feeding
  • People who work night shifts
  • Hypersensitivity to investigational drugs or its additives, or intolerability to metformin
  • Need for use of medications prohibited by the protocol during the study for treatment purpose
  • Significant diseases in cardiovascular, liver, nerve, endocrine or other systems, unable to complete the study or difficult to be used in study analysis
  • Drugs or alcohol abuse

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00347100

Beijing, China
Sponsors and Collaborators
Study Director: Bruno Jolain Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00347100     History of Changes
Other Study ID Numbers: LANTU_L_01051
Study First Received: June 30, 2006
Last Updated: September 14, 2009

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 26, 2017